These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 15954910

  • 1. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.
    Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH.
    Kidney Int; 2005 Jul; 68(1):206-16. PubMed ID: 15954910
    [Abstract] [Full Text] [Related]

  • 2. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
    Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G, ALADIN 2 Study Group.
    PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
    [Abstract] [Full Text] [Related]

  • 3. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P, ALADIN study group.
    Lancet; 2013 Nov 02; 382(9903):1485-95. PubMed ID: 23972263
    [Abstract] [Full Text] [Related]

  • 4. Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.
    Trillini M, Caroli A, Perico N, Remuzzi A, Brambilla P, Villa G, Perna A, Peracchi T, Rubis N, Martinetti D, Caruso M, Leone VF, Cugini D, Carrara F, Remuzzi G, Ruggenenti P, TOOL Study Group.
    Clin J Am Soc Nephrol; 2023 Feb 01; 18(2):223-233. PubMed ID: 36754009
    [Abstract] [Full Text] [Related]

  • 5. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
    Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR, Rossetti S, Harris PC, LaRusso NF, Torres VE.
    J Am Soc Nephrol; 2010 Jun 01; 21(6):1052-61. PubMed ID: 20431041
    [Abstract] [Full Text] [Related]

  • 6. Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.
    Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P, ALADIN-Cardiovascular Study Group.
    Int J Cardiol; 2019 Jan 15; 275():145-151. PubMed ID: 30509370
    [Abstract] [Full Text] [Related]

  • 7. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP.
    Liver Int; 2015 May 15; 35(5):1607-14. PubMed ID: 25369108
    [Abstract] [Full Text] [Related]

  • 8. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP.
    J Hepatol; 2013 Jul 15; 59(1):153-9. PubMed ID: 23499726
    [Abstract] [Full Text] [Related]

  • 9. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, Oftsie T, Madsen C, Edwards M, Glockner J, Kremers WK, Harris PC, LaRusso NF, Torres VE, Masyuk TV.
    Clin J Am Soc Nephrol; 2020 Sep 07; 15(9):1267-1278. PubMed ID: 32843370
    [Abstract] [Full Text] [Related]

  • 10. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP.
    Gastroenterology; 2013 Aug 07; 145(2):357-65.e1-2. PubMed ID: 23665274
    [Abstract] [Full Text] [Related]

  • 11. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
    Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P, ALADIN Study Group.
    Clin Gastroenterol Hepatol; 2016 Jul 07; 14(7):1022-1030.e4. PubMed ID: 26844873
    [Abstract] [Full Text] [Related]

  • 12. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
    Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, Nitatori T, Kobayashi K.
    Clin Exp Nephrol; 2015 Aug 07; 19(4):746-52. PubMed ID: 25351823
    [Abstract] [Full Text] [Related]

  • 13. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 07; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 14. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH, DIPAK-1 Investigators.
    Gastroenterology; 2019 Aug 07; 157(2):481-491.e7. PubMed ID: 31022403
    [Abstract] [Full Text] [Related]

  • 15. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography.
    Sise C, Kusaka M, Wetzel LH, Winklhofer F, Cowley BD, Cook LT, Gordon M, Grantham JJ.
    Kidney Int; 2000 Dec 07; 58(6):2492-501. PubMed ID: 11115083
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
    Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.
    Mayo Clin Proc; 2015 Aug 07; 90(8):1030-7. PubMed ID: 26166166
    [Abstract] [Full Text] [Related]

  • 17. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
    Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P.
    Clin J Am Soc Nephrol; 2010 May 07; 5(5):783-9. PubMed ID: 20185596
    [Abstract] [Full Text] [Related]

  • 18. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation.
    Yamamoto T, Watarai Y, Kobayashi T, Matsuda Y, Tsujita M, Hiramitsu T, Nanmoku K, Goto N, Katayama A, Tominaga Y, Uchida K.
    Transplantation; 2012 Apr 27; 93(8):794-8. PubMed ID: 22491657
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, DIPAK Consortium.
    Am J Kidney Dis; 2014 Mar 27; 63(3):446-55. PubMed ID: 24342522
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q, Lin C, Ji S, Chen J.
    Am J Med Sci; 2012 Dec 27; 344(6):491-7. PubMed ID: 22902868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.